Koen Andries
#76,539
Most Influential Person Now
Scientist
Koen Andries's AcademicInfluence.com Rankings
Koen Andrieschemistry Degrees
Chemistry
#5406
World Rank
#6577
Historical Rank
Quantum Chemistry
#71
World Rank
#71
Historical Rank
Chemical Engineering
#765
World Rank
#785
Historical Rank
Physical Chemistry
#882
World Rank
#942
Historical Rank
Download Badge
Chemistry
Why Is Koen Andries Influential?
(Suggest an Edit or Addition)According to Wikipedia, Koen Andries is a Belgian Janssen Pharmaceutica scientist and professor at the University of Antwerp. In 2005 he and his team published a discovery about a new di-Aryl-Quinoline-based drug , now called bedaquiline, which promises a shorter and simpler treatment for drug resistant Tuberculosis .
Koen Andries's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- A Diarylquinoline Drug Active on the ATP Synthase of Mycobacterium tuberculosis (2005) (1894)
- The challenge of new drug discovery for tuberculosis (2011) (965)
- The diarylquinoline TMC207 for multidrug-resistant tuberculosis. (2009) (756)
- Potent and selective inhibition of HIV-1 replication in vitro by a novel series of TIBO derivatives (1990) (669)
- Multidrug-resistant tuberculosis and culture conversion with bedaquiline. (2014) (556)
- Locations of anti-AIDS drug binding sites and resistance mutations in the three-dimensional structure of HIV-1 reverse transcriptase. Implications for mechanisms of drug inhibition and resistance. (1994) (506)
- Roles of conformational and positional adaptability in structure-based design of TMC125-R165335 (etravirine) and related non-nucleoside reverse transcriptase inhibitors that are highly potent and effective against wild-type and drug-resistant HIV-1 variants. (2004) (492)
- Diarylquinolines target subunit c of mycobacterial ATP synthase. (2007) (468)
- In search of a novel anti-HIV drug: multidisciplinary coordination in the discovery of 4-[[4-[[4-[(1E)-2-cyanoethenyl]-2,6-dimethylphenyl]amino]-2- pyrimidinyl]amino]benzonitrile (R278474, rilpivirine). (2005) (341)
- Randomized Pilot Trial of Eight Weeks of Bedaquiline (TMC207) Treatment for Multidrug-Resistant Tuberculosis: Long-Term Outcome, Tolerability, and Effect on Emergence of Drug Resistance (2012) (339)
- TMC125, a Novel Next-Generation Nonnucleoside Reverse Transcriptase Inhibitor Active against Nonnucleoside Reverse Transcriptase Inhibitor-Resistant Human Immunodeficiency Virus Type 1 (2004) (338)
- Diarylquinolines Are Bactericidal for Dormant Mycobacteria as a Result of Disturbed ATP Homeostasis* (2008) (315)
- Acquired Resistance of Mycobacterium tuberculosis to Bedaquiline (2014) (303)
- Towards a new combination therapy for tuberculosis with next generation benzothiazinones (2014) (291)
- Structure of HIV-1 RT/TIBO R 86183 complex reveals similarity in the binding of diverse nonnucleoside inhibitors (1995) (282)
- TMC125 Displays a High Genetic Barrier to the Development of Resistance: Evidence from In Vitro Selection Experiments (2005) (263)
- Location of Persisting Mycobacteria in a Guinea Pig Model of Tuberculosis Revealed by R207910 (2007) (246)
- Bedaquiline in the treatment of multidrug- and extensively drug-resistant tuberculosis (2015) (239)
- Discovery and development of SQ109: a new antitubercular drug with a novel mechanism of action. (2012) (209)
- Selectivity of TMC207 towards Mycobacterial ATP Synthase Compared with That towards the Eukaryotic Homologue (2008) (205)
- Crystal structures of 8-Cl and 9-Cl TIBO complexed with wild-type HIV-1 RT and 8-Cl TIBO complexed with the Tyr181Cys HIV-1 RT drug-resistant mutant. (1996) (192)
- Delayed bactericidal response of Mycobacterium tuberculosis to bedaquiline involves remodelling of bacterial metabolism (2014) (187)
- Comprehensive analysis of methods used for the evaluation of compounds against Mycobacterium tuberculosis. (2012) (183)
- Rates and Mechanisms of Resistance Development in Mycobacterium tuberculosis to a Novel Diarylquinoline ATP Synthase Inhibitor (2009) (174)
- Structure of HIV-1 reverse transcriptase in a complex with the non-nucleoside inhibitor alpha-APA R 95845 at 2.8 A resolution. (1995) (172)
- Synergistic Activity of R207910 Combined with Pyrazinamide against Murine Tuberculosis (2006) (171)
- Evolution of anti-HIV drug candidates. Part 3: Diarylpyrimidine (DAPY) analogues. (2001) (169)
- Sterilizing Activity of Novel TMC207- and PA-824-Containing Regimens in a Murine Model of Tuberculosis (2011) (166)
- Potent and highly selective human immunodeficiency virus type 1 (HIV-1) inhibition by a series of alpha-anilinophenylacetamide derivatives targeted at HIV-1 reverse transcriptase. (1993) (162)
- In Vitro Antimycobacterial Spectrum of a Diarylquinoline ATP Synthase Inhibitor (2007) (151)
- Bactericidal mode of action of bedaquiline. (2015) (147)
- Two groups of rhinoviruses revealed by a panel of antiviral compounds present sequence divergence and differential pathogenicity (1990) (146)
- Sterilizing Activities of Novel Combinations Lacking First- and Second-Line Drugs in a Murine Model of Tuberculosis (2012) (141)
- Genetic Basis for Natural and Acquired Resistance to the Diarylquinoline R207910 in Mycobacteria (2006) (138)
- Essentiality of FASII pathway for Staphylococcus aureus (2010) (138)
- Combinations of R207910 with Drugs Used To Treat Multidrug-Resistant Tuberculosis Have the Potential To Shorten Treatment Duration (2006) (136)
- Comparison of the Anti-Influenza Virus Activity of RWJ-270201 with Those of Oseltamivir and Zanamivir (2001) (135)
- Mutations in pepQ Confer Low-Level Resistance to Bedaquiline and Clofazimine in Mycobacterium tuberculosis (2016) (134)
- An antiviral target on reverse transcriptase of human immunodeficiency virus type 1 revealed by tetrahydroimidazo-[4,5,1-jk] [1,4]benzodiazepin-2 (1H)-one and -thione derivatives. (1991) (130)
- A computational model of the inhibition of Mycobacterium tuberculosis ATPase by a new drug candidate R207910 (2007) (129)
- Evolution of anti-HIV drug candidates. Part 2: Diaryltriazine (DATA) analogues. (2001) (128)
- In Vitro Interactions between New Antitubercular Drug Candidates SQ109 and TMC207 (2010) (123)
- Crystal structures for HIV-1 reverse transcriptase in complexes with three pyridinone derivatives: a new class of non-nucleoside inhibitors effective against a broad range of drug-resistant strains. (2005) (123)
- In vitro activity of pirodavir (R 77975), a substituted phenoxy-pyridazinamine with broad-spectrum antipicornaviral activity (1992) (121)
- Unexpected high prevalence of resistance-associated Rv0678 variants in MDR-TB patients without documented prior use of clofazimine or bedaquiline (2016) (121)
- Probing the Interaction of the Diarylquinoline TMC207 with Its Target Mycobacterial ATP Synthase (2011) (120)
- Multivariate analysis of human immunodeficiency virus type 1 neutralization data (1996) (103)
- Synthesis of novel diarylpyrimidine analogues and their antiviral activity against human immunodeficiency virus type 1. (2005) (103)
- Substituted benzimidazoles with nanomolar activity against respiratory syncytial virus. (2003) (101)
- Intranasal pirodavir (R77,975) treatment of rhinovirus colds (1995) (98)
- Structures of poliovirus complexes with anti-viral drugs: implications for viral stability and drug design (1994) (98)
- Safety and efficacy of intranasal pirodavir (R77975) in experimental rhinovirus infection (1992) (95)
- Bedaquiline and Pyrazinamide Treatment Responses Are Affected by Pulmonary Lesion Heterogeneity in Mycobacterium tuberculosis Infected C3HeB/FeJ Mice (2016) (93)
- Susceptibility of Mycobacterium abscessus to Antimycobacterial Drugs in Preclinical Models (2015) (88)
- Pharmacokinetics and Pharmacodynamics of TMC207 and Its N-Desmethyl Metabolite in a Murine Model of Tuberculosis (2011) (87)
- The cytochrome bd-type quinol oxidase is important for survival of Mycobacterium smegmatis under peroxide and antibiotic-induced stress (2015) (87)
- Binding of a potent small-molecule inhibitor of six-helix bundle formation requires interactions with both heptad-repeats of the RSV fusion protein (2009) (85)
- Sterilizing activity of R207910 (TMC207)-containing regimens in the murine model of tuberculosis. (2009) (84)
- A comparison of the anti-rhinoviral drug binding pocket in HRV14 and HRV1A. (1994) (82)
- Selection of a respiratory syncytial virus fusion inhibitor clinical candidate. 2. Discovery of a morpholinopropylaminobenzimidazole derivative (TMC353121). (2008) (81)
- Evolution of anti-HIV drug candidates. Part 1: From α-Anilinophenylacetamide (α-APA) to imidoyl thiourea (ITU) (2001) (76)
- Suppression of colds in human volunteers challenged with rhinovirus by a new synthetic drug (R61837) (1989) (75)
- A once-weekly R207910-containing regimen exceeds activity of the standard daily regimen in murine tuberculosis. (2009) (75)
- Diarylquinolines, synthesis pathways and quantitative structure--activity relationship studies leading to the discovery of TMC207. (2011) (74)
- Novel Antibiotics Targeting Respiratory ATP Synthesis in Gram-Positive Pathogenic Bacteria (2012) (74)
- Comparative study of starch degradation and amylase production by ascomycetous yeast species (1984) (74)
- Sterilizing Activity of Second-Line Regimens Containing TMC207 in a Murine Model of Tuberculosis (2011) (67)
- Impact of the Interaction of R207910 with Rifampin on the Treatment of Tuberculosis Studied in the Mouse Model (2008) (67)
- Time to detection of the growth of Mycobacterium tuberculosis in MGIT 960 for determining the early bactericidal activity of antituberculosis agents (2010) (64)
- A TIBO derivative, R82913, is a potent inhibitor of HIV-1 reverse transcriptase with heteropolymer templates. (1991) (63)
- Potential use of antiviral agents in polio eradication. (2008) (63)
- A Series of Diaryltriazines and Diarylpyrimidines Are Highly Potent Nonnucleoside Reverse Transcriptase Inhibitors with Possible Applications as Microbicides (2004) (60)
- New tetrahydroimidazo[4,5,1-jk][1,4]-benzodiazepin-2(1H)-one and -thione derivatives are potent inhibitors of human immunodeficiency virus type 1 replication and are synergistic with 2',3'-dideoxynucleoside analogs (1994) (59)
- Short-course chemotherapy with TMC207 and rifapentine in a murine model of latent tuberculosis infection. (2011) (57)
- Human rhinovirus 14 complexed with antiviral compound R 61837. (1991) (55)
- Bactericidal Potencies of New Regimens Are Not Predictive of Their Sterilizing Potencies in a Murine Model of Tuberculosis (2010) (54)
- Short duration aerosols of JNJ 2408068 (R170591) administered prophylactically or therapeutically protect cotton rats from experimental respiratory syncytial virus infection. (2003) (54)
- Antiviral and lung protective activity of a novel respiratory syncytial virus fusion inhibitor in a mouse model (2010) (52)
- Bactericidal activity of the diarylquinoline TMC207 against Mycobacterium tuberculosis outside and within cells. (2010) (51)
- A comparison of WIN 51711 and R 78206 as stabilizers of poliovirus virions and procapsids. (1991) (50)
- 6-Cyano Analogues of Bedaquiline as Less Lipophilic and Potentially Safer Diarylquinolines for Tuberculosis (2017) (48)
- Selection of a respiratory syncytial virus fusion inhibitor clinical candidate, part 1: improving the pharmacokinetic profile using the structure-property relationship. (2007) (46)
- On the detection of multiple-binding modes of ligands to proteins, from biological, structural, and modeling data (2003) (46)
- Bactericidal Activities of R207910 and Other Newer Antimicrobial Agents against Mycobacterium leprae in Mice (2006) (45)
- A comparative test of fifteen compounds against all known human rhinovirus serotypes as a basis for a more rational screening program. (1991) (43)
- ATP Synthase Inhibition of Mycobacterium avium Is Not Bactericidal (2009) (43)
- A dual chamber model of female cervical mucosa for the study of HIV transmission and for the evaluation of candidate HIV microbicides. (2007) (43)
- Design, synthesis, and SAR of a novel pyrazinone series with non-nucleoside HIV-1 reverse transcriptase inhibitory activity. (2005) (42)
- Synthesis and evaluation of analogues of the tuberculosis drug bedaquiline containing heterocyclic B-ring units (2017) (41)
- Alignment of capsid protein VP1 sequences of all human rhinovirus prototype strains: conserved motifs and functional domains. (2006) (41)
- In vitro activity of bedaquiline against rapidly growing nontuberculous mycobacteria (2017) (37)
- Prevention of Drug Carryover Effects in Studies Assessing Antimycobacterial Efficacy of TMC207 (2008) (35)
- Thermal inactivation of oral polio vaccine: contribution of RNA and protein inactivation (1994) (34)
- 3-iodo-4-phenoxypyridinones (IOPY's), a new family of highly potent non-nucleoside inhibitors of HIV-1 reverse transcriptase. (2003) (30)
- Study of the dynamics of neutralization escape mutants in a chimpanzee naturally infected with the simian immunodeficiency virus SIVcpz-ant (1997) (30)
- 4-Benzyl and 4-benzoyl-3-dimethylaminopyridin-2(1H)-ones: in vitro evaluation of new C-3-amino-substituted and C-5,6-alkyl-substituted analogues against clinically important HIV mutant strains. (2005) (29)
- Synthesis and anti-HIV-1 activity of 4,5,6,7-tetrahydro-5-methylimidazo[4,5,1-jk][1,4]benzodiazepin- 2(1H)-one (TIBO) derivatives. (1991) (28)
- Antiviral Activity of TMC353121, a Respiratory Syncytial Virus (RSV) Fusion Inhibitor, in a Non-Human Primate Model (2015) (27)
- An Appraisal of the Efficacy of the Antiviral R 61837 in Rhinovirus Infections in Human Volunteers (1990) (24)
- The Diarylquinoline R207910 Is Bactericidal against Mycobacterium leprae in Mice at Low Dose and Administered Intermittently (2009) (24)
- Correlations between Factors Determining the Pharmacokinetics and Antiviral Activity of HIV-1 Non-Nucleoside Reverse Transcriptase Inhibitors of the Diaryltriazine and Diarylpyrimidine Classes of Compounds (2004) (23)
- Pharmacokinetics-Pharmacodynamics of a Respiratory Syncytial Virus Fusion Inhibitor in the Cotton Rat Model (2010) (22)
- Allosteric inhibition of human immunodeficiency virus type 1 reverse transcriptase by tetrahydroimidazo[4,5,1-jk][1,4]benzodiazepin-2(1H)-one and -thione compounds. (1992) (21)
- Synthesis and anti-HIV activity of 1,3,4,5-tetrahydro-2H-1,4-benzodiazepin-2-one (TBO) derivatives. truncated 4,5,6,7-tetrahydro-5-methylimidazo[4,5,1-jk][1,4]benzodiazepin-2(1H)-ones (TIBO) analogues (1999) (20)
- Discrepancy between infectivity and antigenicity stabilization of oral poliovirus vaccine by a capsid-binding compound (1994) (20)
- Capsid and RNA stabilisation of the oral polio vaccine. (2001) (19)
- In vitro culture conditions affecting minimal inhibitory concentration of bedaquiline against M. tuberculosis. (2016) (19)
- The ATP synthase inhibitor bedaquiline interferes with small-molecule efflux in Mycobacterium smegmatis (2014) (19)
- Activity of a Long-Acting Injectable Bedaquiline Formulation in a Paucibacillary Mouse Model of Latent Tuberculosis Infection (2019) (18)
- Synthesis and biological evaluation of C-5 methyl substituted 4-arylthio and 4-aryloxy-3-Iodopyridin-2(1H)-one type anti-HIV agents. (2009) (18)
- Antiviral capsid-binding compounds can inhibit the adsorption of minor receptor rhinoviruses. (1994) (16)
- In vitro activity of R 61837, a new antirhinovirus compound (2005) (15)
- 4-benzyl- and 4-benzoyl-3-dimethylaminopyridin-2(1H)-ones, a new family of potent anti-HIV agents: optimization and in vitro evaluation against clinically important HIV mutant strains. (2004) (15)
- Structure-activity relationship in the 3-iodo-4-phenoxypyridinone (IOPY) series: The nature of the C-3 substituent on anti-HIV activity. (2007) (14)
- Evolution of anti-HIV drug candidates. Part 1: From alpha-anilinophenylacetamide (alpha-APA) to imidoyl thiourea (ITU). (2001) (13)
- Molecular modeling of HIV-1 reverse transcriptase drug-resistant mutant strains: implications for the mechanism of polymerase action. (1997) (12)
- Specific HIV-1 reverse transcriptase inhibitors. (1992) (11)
- Mode of action of 2-furylmercury chloride, an anti-rhinovirus compound. (2004) (11)
- [R207910 (TMC207): a new antibiotic for the treatment of tuberculosis]. (2010) (10)
- Evaluation of the efficacy and tolerance of R 018893, R 089439 (loviride) and placebo in asymptomatic HIV-1-infected patients. Loviride Collaborative Study Group. (1996) (10)
- Lack of quantitative correlation between inhibition of replication of rhinoviruses by an antiviral drug and their stabilization (2005) (10)
- Preparation of quinoline derivatives and their use as mycobacterial inhibitors (2006) (9)
- In vitro evaluation of the effect of temporary removal of HIV drug pressure. (2000) (9)
- Evaluation of six months sputum culture conversion as a surrogate endpoint in a multidrug resistant-tuberculosis trial (2018) (9)
- Stabilisation of poliovirus with pirodavir. (1996) (8)
- New Anti-Tuberculosis Drugs in Clinical Development: An Overview (2009) (8)
- Study of the parameters of binding of R 61837 to human rhinovirus 9 and immunobiochemical evidence of capsid-stabilizing activity of the compound (1992) (7)
- TIBO derivatives: a new class of highly potent and specific inhibitors of HIV-1 replication. (1992) (7)
- R75761, a lead compound for the development of antiviral drugs in late stage poliomyelitis eradication strategies and beyond. (2008) (7)
- Synthesis, characterization and biological activity of fluorescently labeled bedaquiline analogues (2016) (6)
- Drug resistant rhinoviruses from the nose of experimentally treated volunteers (2005) (6)
- Evolution of anti-HIV drug candidates diaryltriazines (DATA) analogs (2001) (5)
- Early bactericidal activity, tolerability, and pharmacokinetics of the investigational diarylquinoline TMC207 (2006) (5)
- Potent and selective inhibition of HIV-1 replication in vitro by a novel series of tetrahydro-imidazo[4,5,1-JK][1,4]-benzzodiazepin-2(1H)-one and -thione (TIBO) derivatives (1990) (5)
- Discovery of Pirodavir, a Broad-Spectrum Inhibitor of Rhinoviruses (1993) (4)
- New [4,5,1-JK][1,4]benzodiazepin-2(1H)-one and -thione derivatives are potent inhibitors of human immunodeficiency virus type 1 and are synergistic with 2',3'-dideoxynucleoside analogs (1994) (4)
- Combating drug-resistant tuberculosis: the unexpected benefits of bedaquiline. (2017) (4)
- Synthesis and anti-HIV-1 activity of 4,5,6,7-tetrahydro-5-methylimidazo benzodiazepin-2(1H)-one (TIBO) derivatives (1991) (4)
- 3-Iodo-4-phenoxypyridinones (IOPY′s), a New Family of Highly Potent Non-Nucleoside Inhibitors of HIV-1 Reverse Transcriptase. (2004) (3)
- Quinoline derivatives and their use as inhibitors mycobacterial (2003) (3)
- Efficacy of Long-Acting Bedaquiline Regimens in a Mouse Model of Tuberculosis Preventive Therapy. (2021) (3)
- In vitro Anti-mycobacterial Spectrum of a Diarylquinoline ATP Synthase (2007) (3)
- Fully weekly antituberculosis regimen: a proof-of-concept study (2020) (2)
- 1H)-One and-Thione Derivatives ArePotent Inhibitors ofHuman Immunodeficiency Virus Type1Replication andAre Synergistic with2',3'-Dideoxynucleoside Analogs (1994) (2)
- 1.4 Diastereomers, Enantiomers and Bioactivity. TMC207: A New Candidate for the Treatment of Tuberculosis (2012) (2)
- Structures of poliovirus complexes with antiviral drugs: implications for drug design, capsid stability, and viral uncoating (1994) (2)
- Synthesis and Anti‐HIV‐1 Activity of 4,5,6,7‐Tetrahydro‐5‐methylimidazo(4,5,1‐jk)(1,4)benzodiazepin‐2 (1H)‐one (TIBO) Derivatives. Part 2. (2010) (2)
- A comparative test of 15 compounds against all rhinoviruses as a basis for a more rational screening (1991) (2)
- New antiviral target on HIV-1 reverse transcriptase revealed by TIBO derivatives (1991) (2)
- Study of the binding parameters of R 61837 to HRV9 and immunobiochemical evidence for a capsid stabilizing activity of the compound (1992) (2)
- Preparation of piperidine-amino-benzimidazole derivatives as inhibitors of respiratory syncytial virus replication (2005) (2)
- Synergistic activity of R 207910 combined with pyrazinamide in murine tuberculosis (2)
- Crystal structures of 8-Cl and 9-Cl TIBO complexed with Tyr181Cys HIV-1 RT drug-resistant mutant (1996) (1)
- IN VITRO SYNERGY OF BEDAQUILINE AND PYRAZINOIC ACID (2015) (1)
- Real-time characterization of the interaction of HIV-1-specific inhibitors with their binding site at the HIV-1 reverse transcriptase (RT) using surface plasmon resonance and biosensor technology (1993) (1)
- Etravirine: From TMC125 to Intelence: A Treatment Paradigm Shift for HIV‐Infected Patients (2011) (1)
- Crystal structure of HIV-1 reverse transcriptase (RT) in complex with R221239 (2005) (1)
- TIBO R82913, a new HIV-1 inhibiting agent, does not inhibit hematopoietic progenitor cells. (1991) (1)
- Quinoline derivatives antibacterials (2007) (1)
- Impact of Rv0678 mutations on patients with drug-resistant TB treated with bedaquiline (2022) (1)
- Allosteric properties of heterodimeric HIV-1 reverse transcriptase (1991) (1)
- Interaction of TIBO and TIBO-like compounds with HIV-1 RT (1991) (1)
- The challenge of new drug discovery for (2011) (1)
- Comparison of RT gene sequences from HIV-1 strains with different sensitivity to TIBO derivatives (1992) (1)
- Preparation of aminohydroxyphenylbutylquinolines as antibacterials (2006) (1)
- Synthesis and anti-HIV activity of 1,3,4,5-tetrahydro-2H-1,4-benzodiazepin-2-one (TBO) derivatives. Truncated 4,5,6,7-tetrahydro-5-methylimidazo[4,5,1-jk][1,4]benzodiazepin-2( 1H)-on es (TIBO) analogues. (1999) (1)
- Oseltamivir and Zanamivir Activity of RWJ-270201 with Those of Comparison of the Anti-Influenza Virus (2001) (1)
- Potent and highly selective HIV-1 specific inhibition by a new series of alfa- anilino-phenylacetamide (alfa-APA) derivatives targeted at HIV-1 RT (1992) (1)
- Automation of an antiviral screening using a Zymate Laboratory Robot (1993) (1)
- Antirhinovirus spectrum and mechanism of action of R 77975 (1991) (1)
- Solution structure of the respiratory syncytial virus (RSV)six-helix bundle complexed with TMC353121, a small-moleucule inhibitor of RSV (2009) (0)
- Potent and highly selective HIV-1 specific inhibition by a new series of phenylacetamide derivatives targeted at HIV-1 RT (1992) (0)
- HIV-1 specific inhibition of reverse transcriptase by TIBO-derivatives: a new mechanism of antiviral action discovered by drug screening (1990) (0)
- Rapid emergence of HIV-1 resistance to R82913 in only a minority of treated patients (1993) (0)
- Inhibiting pyrimidines of hiv replication. (1999) (0)
- Cytochrome bd as survival factor in mycobacteria (2016) (0)
- TIBO derivatives represent a new lead of potent and selective HIV-1 inhibitors that interact with a reverse transcriptase-associated process (1990) (0)
- Potent and highly selective HIV-1 specific inhibition by a new series of alfa-anilino phenyl acetamide (alfa-APA) derivatives targeted at HIV-1 reverse transcriptase (1992) (0)
- Preparation of aminobenzimidazoles as inhibitors of respiratory syncytial virus replication (2005) (0)
- Aminobenzimidazole derivatives as inhibitors of the replication of the respiratory syncytial virus (2004) (0)
- Activity of TMC207 Against Mycobacterium avium In Vitro and in the Mouse Model (2008) (0)
- Rates and Mechanisms of Resistance Development in Mycobacterium tuberculosis to a Novel Diarylquinoline ATP Synthase Inhibitor (cid:1) † (2010) (0)
- Efficacy Of TMC207 In A Murine Model Of Latent Tuberculosis Infection (LTBI) (2011) (0)
- Amino-benzimidazole derivatives as inhibitors of replication of respiratory syncytial virus. (2004) (0)
- Translational pharmacokinetic modelling & simulation of an experimental long-acting injectable formulation of bedaquiline (0)
- Preparation of morpholine containing benzimidazoles as inhibitors of respiratory syncytial virus replication (2005) (0)
- Piperidinamino-benzimidazole derivatives al respiratory syncytial virus replication inhibitors (2004) (0)
- Treatment of HIV-infected cell cultures with high concentrations of anti-HIV drugs for several days does not prevent resumption of virus production upon removal of the antivirals (1998) (0)
- THE ROLE OF CYTOCHROME BD IN MYCOBACTERIUM SMEGMATIS IN PROTECTION AGAINST REACTIVE OXYGEN SPECIES AND ANTIBACTERIALS In collaboration with : (2015) (0)
- Isolation and characterization of clinical HIV-1 strains with different sensitivities to TIBO derivatives (1993) (0)
- Cyclodextrin containing pharmaceutical preparations (1988) (0)
- Chapter 9 The Role of Exploratory Data Analysis in the Development of Novel Antiviral Compounds (1990) (0)
- Discovery and development of TIBO as a potential anti-AIDS therapeutic (1992) (0)
- Foerfarande Foer framstaellning The compositions of antiviral innehaollande cyclodextrin. (1988) (0)
- Bedaquiline (R207910 or TMC207), a new candidate for the treatment of multidrug resistant tuberculosis (2016) (0)
- Morpholinylholdige benzimidazoles as inhibitors of the respiratory syncytial virus replication (2004) (0)
- Discovery, development and characterization of agents active against the AIDS virus. (1995) (0)
- Inhibitatoria pyramidine derived from HIV. (1999) (0)
- Crystal structure of HIV-1 reverse transcriptase (RT) in complex with JANSSEN-R165481 (2005) (0)
- The TIBO-site on HIV-1 reverse transcriptase represents a new target for anti-HIV chemotherapy (1991) (0)
- Selective inhibitory effect of a TIBO compound, R82150, on the activity of HIV-1 reverse transcriptase (1991) (0)
- Thermal Inactivation ofOralPolio Vaccine: Contribution of RNA andProtein Inactivation (1994) (0)
- TIBO derivatives: a new class of potent and selective inhibitors of HIV-1 replication (1991) (0)
- Pyrimidine derivatives HIV inhibitors. (1999) (0)
- S1.9 ATP synthase as target of the tuberculosis antibiotic diarylquinoline (2008) (0)
- Potential Use of Antiviral Agents in Polio Eradication (2008) (0)
- 5- or 6-substituted benzimidazole derivatives as inhibitors of the replication of the respiratory syncytial virus (2004) (0)
- Quinoline derivatives and their use as inhibitors of mycobacteria. (2003) (0)
- POLIOVIRUS (TYPE 3, SABIN STRAIN) (P3/SABIN, P3/LEON/12A(1)B) COMPLEXED WITH R78206 (1996) (0)
- Piperidinamino-benzimidazole derivative as inhibitors of the replication of the respiratory syncytial virus (2004) (0)
- Inhibitors of respiratory syncytialvirusreplikation (2000) (0)
- Comparative Activity of Anti-Enteroviral Agents Against Poliovirus Replication In Vitro (2007) (0)
- POLIOVIRUS (TYPE 3, SABIN STRAIN, MUTANT 242-H2) COMPLEXED WITH R78206 (1996) (0)
- Small-molecule Inhibition of Respiratory Syncytial Virus Fusion: It Takes Two to Tango (2010) (0)
- Mode of action of 2-furylmecury chloride, a new antirhinovirus compound (2000) (0)
- Resea R ch aR ticle special Focus: Neglected diseases (2011) (0)
- Preparation of 5- or 6-substituted benzimidazole derivatives as inhibitors of respiratory syncytial virus replication (2005) (0)
- POLIOVIRUS (TYPE 3, SABIN STRAIN) (P3/SABIN, P3/LEON/12A(1)B) COMPLEXED WITH R77975 (1996) (0)
- HIV-1 specific phenylacetamide derivatives: a novel class of reverse transcriptase inhibitors with potent and selective antiviral activity in vitro (1992) (0)
- POLIOVIRUS (TYPE 1, MAHONEY STRAIN) COMPLEXED WITH R78206 (1996) (0)
This paper list is powered by the following services:
Other Resources About Koen Andries
What Schools Are Affiliated With Koen Andries?
Koen Andries is affiliated with the following schools:
